Currently, research to determine the role ofnon-myeloablative (a.k.a. "mini" transplants)in CLL is underway. Non-myeloablative transplants rely less on the toxicity of chemotherapy and more on the "graft-versus-leukemia" effect to treat cancer. This type of therapy may provide a treatment o...
Chronic lymphocytic leukemia (CLL) is a disease predominantly of the elderly, with a median age at diagnosis of 72 years. Although many advances have been made in the care of these patients with the addition of a variety of active drugs to the therapeutic armamentarium, treatment in the ...
Remarkable progress has been made over the past 6 years in targeted therapy for patients with chronic lymphocytic leukemia (CLL). Prior evolution in chemoimmunotherapy (CIT) led to development of progressively more effective combinations, but at the cost of myelosuppression and risk for infection and...
AJ Lanigan:Take a while. But whatever that number is, roughly 10% of those cells make up theimmune system. So we’re looking at 10 to 12 trillion cells. Now that’s more cells than you have brain and central nervous system. That’s more cells than you have skin. You know skin is...
My New Year's resolutions have evolved from seeking external goals to embracing personal growth and appreciating each day. January 21st 2025 Waiting for Results After My CLL Diagnosis Karen Cohn Waiting for results of a CT scan after a cancer diagnosis is agonizing, as I anxiously await news on...
The choice of stem cell depends on accessibility to the donor, disease diagnosis, urgency for the transplant, and centre preference (Elfeky et al.2019). 2.3.1Peripheral Blood Stem Cells PBSCs have been increasingly used in both auto- and allo-HSCT. Mobilization of haematopoietic stem cells to...
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients Brooke McCormick Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.Recent...
This is most likely due to earlier (HLH) is a life-threatening disease of severe diagnosis; improved supportive care, including hyper inflammation caused by uncontrolled the initiation of bacterial and fungal prophylaxis; proliferation of activated lymphocytes and and early referral for HSCT (Booth et...
Interleukin-2 (IL-2)-diphtheria toxin fusion protein is a biological product used for the treatment of cutaneous T-cell lymphoma (CTCL) in adults.
At the time when he wanted to recommence therapy, the disease had recurred with 35% blasts on the blood smear. The mutational spectrum at this time showed positive results for all mutations present at diagnosis, with an additional mutation in TP53. Question What is the outlook of patients ...